Protalix BioTherapeutics(FRA) PBD

Market CapN/A

Since IPON/A

5 YearN/A

1 YearN/A

1 MonthN/A

N/A

Protalix BioTherapeutics Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$69.07

Net Income (TTM)

$16.19

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

N/A

PBD News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Protalix BioTherapeutics

Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. Its products include Alidornase alfa, PRX-115 and PRX-11. The company was by Yoseph Shaaltiel in 1993 and is headquartered in Carmiel, Israel.

Industry

Biotechnology

Sector

Health Care

Employees

226

CEO

Dror Bashan, MBA

Website

www.protalix.com

PBD Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

N/A

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

N/A

Payout Ratio

N/A

Stock Overview

Market Cap

N/A

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Protalix BioTherapeutics Performance Analysis

Protalix BioTherapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 45,327,464	39.7%
2023	2023-12-31	USD 60,580,016	33.6%
2024	2024-12-31	USD 49,366,235	-18.5%
2025	2025-12-31	USD 46,734,920	-5.3%

Protalix BioTherapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -0.29	-44.6%
2023	2023-12-31	USD 0.08	N/A
2024	2024-12-31	USD 0.03	-57.7%
2025	2025-12-31	USD -0.07	N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$17.11

+1.2%

Gross Profit

$10.44

+1.2%

Gross Margin

60.99%

+1.0%

Market Cap

N/A

Market Cap/Employee

$0.72

N/A

Employees

226

N/A

Net Income

$3.25

+22.5%

EBITDA

$4.37

+3.2%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$32.67

+65.0%

Total Debt

$8.05

+1.8%

Accounts Receivable

$14.43

+1.8%

Inventory

$28.24

+1.6%

Long Term Debt

$6.60

+2.0%

Short Term Debt

$1.46

+1.2%

Return on Assets

19.82%

+2.6%

Return on Invested Capital

-31.58%

N/A

Free Cash Flow

-$9.34

+2.0%

Operating Cash Flow

-$8.83

+2.1%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

^GSPCS&P 500

^GSPCS&P 500$7,684.24-0.00%

^DJIDJI

^DJIDJI$53,254.61-0.01%

^IXICNASDAQ

^IXICNASDAQ$26,319.55-0.00%

BTCBitcoin

BTCBitcoin$78,890.00-0.00%

SPCXSPCX

SPCXSPCX$142.81+0.01%

AAPLAAPL

AAPLAAPL$315.25-0.01%

AMZNAMZN

AMZNAMZN$258.45-0.03%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$71.92+0.00%

WETOWetour Robotics

WETOWetour Robotics$5.48-0.04%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.63+0.02%

INTCIntel

INTCIntel$89.51+0.00%

NVDANvidia

NVDANvidia$220.78+0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.97+0.11%

IBITiShares Bitcoin Trust

IBITiShares Bitcoin Trust$44.67+0.02%

Questions About PBD

What is the current price of Protalix BioTherapeutics?

Protalix BioTherapeutics is trading at N/A per share.

What is the 52-week range for Protalix BioTherapeutics?

Over the past 52 weeks, Protalix BioTherapeutics has traded between N/A and N/A.

How much debt does Protalix BioTherapeutics have?

As of the most recent reporting period, Protalix BioTherapeutics reported total debt of $8.05M.

How much cash does Protalix BioTherapeutics have on hand?

Protalix BioTherapeutics reported $24.61M in cash and cash equivalents in its most recent financial results.

What is Protalix BioTherapeutics’s dividend yield?

Protalix BioTherapeutics does not currently have a dividend yield.

Protalix BioTherapeutics(FRA) PBD

Protalix BioTherapeutics Financials at a Glance

PBD News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Protalix BioTherapeutics

PBD Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Protalix BioTherapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About PBD

What is the current price of Protalix BioTherapeutics?

What is the 52-week range for Protalix BioTherapeutics?

How much debt does Protalix BioTherapeutics have?

How much cash does Protalix BioTherapeutics have on hand?

What is Protalix BioTherapeutics’s dividend yield?

Premium Investing Services